Source: International Congress 2019 – Management of airway diseases in primary care
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. Azzi (Sydney, Australia), V. Kritikos (Sydney, Australia), D. Price (Aberdeen, United Kingdom), M. Peters (Sydney, Australia), P. Srour (Sydney, Australia), B. Cvetkovski (Sydney, Australia), S. Bosnic-Anticevich (Sydney, Australia). Reliever overuse when treatable traits go untreated.. 5151

Member's Comments

No comment yet.

Related content which might interest you: Treatable traits as predictors of SABA overuse in the community. Source: International Congress 2019 – Epidemiology of airway diseases in primary care Year: 2019 Prevalence of non-pharmacological treatable traits in patients with asthma Source: Virtual Congress 2020 – New insights into determinants of patient-reported outcomes in chronic respiratory diseases Year: 2020 Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option? Source: Eur Respir J 2005; 26: 819-828 Year: 2005 Once-daily indacaterol/glycopyrronium (IND/GLY) reduces use of rescue medication versus twice-daily salmeterol/fluticasone (SFC) in patients with moderate-to-very severe COPD: results from the FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 How can treatable traits be used in severe exacerbations? Source: Research Seminar 2021 – Unravelling severe exacerbations of COPD – CICERO an ERS CRC Year: 2021 Budesonide/formoterol single inhaler therapy (SiT) provides superior asthma control compared with fixed dose (FD) budesonide or budesonide/formoterol in patients with severe persistent asthma Source: Eur Respir J 2004; 24: Suppl. 48, 509s Year: 2004 Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma Source: Eur Respir J, 51 (1) 1701688; 10.1183/13993003.01688-2017 Year: 2018 Budesonide/formoterol maintenance and reliever therapy use in elderly asthma patients Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010 Budesonide/formoterol maintenance and reliever therapy versus fluticasone/salmeterol fixed-dose treatment in patients with COPD Source: Virtual Congress 2020 – Advances in pharmacological treatment of COPD Year: 2020 Predictive factors for asthma control according to ACQ5 in asthma patients treated with budesonide/formoterol maintenance and reliever therapy. Results from the EuroSMART study Source: Annual Congress 2010 - Pharmacological modulation of biomarkers and management Year: 2010 Influence of psychiatric disorders in patients treated with Varenicline. Source: International Congress 2017 – Smoking cessation treatment and e-cigarettes Year: 2017 Resource utilization and economic impact of switching uncontrolled asthma and exacerbating COPD patients on monotherapy to fixed dose combination treatment in Germany Source: Annual Congress 2012 - Looking at the cost effectiveness of asthma and COPD treatment by novel drugs and improved management Year: 2012 Formoterol turbuhaler compared with salbutamol as reliever medication in asthma: outcomes from the RELIEF study in patients across different severities and age groups Source: Eur Respir J 2002; 20: Suppl. 38, 45s Year: 2002 Formoterol turbuhaler is effective and safe as maintenance or maintenance plus reliever therapy in patients with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2002; 20: Suppl. 38, 243s Year: 2002 Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma Year: 2016 Effect of treatment with tiotropium bromide 18 mcg on asthma control and asthma-related quality of life in patients with asthma-COPD overlap syndrome. Source: International Congress 2017 – Techniques to treat asthma Year: 2017 Overall and cardiovascular safety of aclidinium/formoterol fixed-dose combination versus salmeterol/fluticasone in patients with COPD Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015 QVA149 is more efficacious than tiotropium and salmeterol/fluticasone combination (SFC) in improving patient-reported outcomes and lung function in COPD patients with moderate-to-severe baseline dyspnoea: The IGNITE trials Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 Budesonide/formoterol maintenance and reliever therapy compared to conventional best practice in the treatment of persistent asthma Source: Eur Respir J 2007; 30: Suppl. 51, 616s Year: 2007 Indacaterol/glycopyrronium (IND/GLY) delays clinically important deterioration (CID) versus salmeterol/fluticasone (SFC) in symptomatic COPD patients: LANTERN/ILLUMINATE pooled analysis Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016